

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GENERTEC UNIVERSAL MEDICAL GROUP
COMPANY LIMITED**

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 2666)

**(1) RESIGNATION OF EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF EXECUTIVE DIRECTOR; AND
(3) CHANGES OF CHAIRPERSON OF THE BOARD, COMPOSITION OF
BOARD COMMITTEES,
AND AUTHORISED REPRESENTATIVE OF THE COMPANY**

The Board announces that with effect from 16 May 2024, Ms. Peng resigned as an executive Director, the chairwoman of the Board, the Nomination Committee, and the Strategy Committee, and the Authorised Representative.

The Board is pleased to announce that with effect from 16 May 2024, Mr. Chen Shisu was appointed as an executive Director, the chairman of the Board, the Nomination Committee, and the Strategy Committee, and the Authorised Representative.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Genertec Universal Medical Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Peng Jiahong (“**Ms. Peng**”) resigned as an executive Director, the chairwoman of the Board, the nomination committee of the Board (the “**Nomination Committee**”), and the strategy committee of the Board (the “**Strategy Committee**”), and the authorised representative of the

Company (the “**Authorised Representative**”) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) due to her other work arrangements, all with effect from 16 May 2024.

Ms. Peng has confirmed that she has no disagreement with the Board and she is not aware of other matters in connection with her resignation that need to be brought to the attention of the Company’s shareholders (the “**Shareholders**”) and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

With her outstanding professional acumen, extensive industry experience, unwavering tenacity and entrepreneurial passion, Ms. Peng has laid a solid foundation for the Company’s strategic advancements, successful implementation of various strategic initiatives, and high-quality development of a central state-owned listed company in the medical and healthcare industry. She has led the Company to achieve continuous breakthroughs in the path of central state-owned enterprises’ medical care services and industry-finance integration. The Board would like to express its sincere gratitude to Ms. Peng for her valuable contribution to the Company’s development during her tenure and throughout her nearly twenty-year career.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that with effect from 16 May 2024, Mr. Chen Shisu (“**Mr. Chen**”) was appointed as an executive Director.

The biographical details of Mr. Chen are set out below:

Mr. Chen Shisu (陳仕俗先生), aged 52, has extensive experience in strategic planning and capital management. Mr. Chen has served as the deputy chief economist (副總經濟師) of the Company’s controlling shareholder, China General Technology (Group) Holding Co., Ltd. (中國通用技術(集團)控股有限公司, “**GT-PRC**”) since August 2022. He has served as the chairman and the secretary of the Party Committee (黨委書記) of General Technology Group Medical Management Technology Co., Ltd. (通用技術集團健康管理科技有限公司) since April 2023 and July 2023, respectively. He also served as the chairman and the secretary of the Party Committee of Aerospace Medical & Healthcare Technology Group Co., Ltd. (航天醫療健康科技集團有限公司), previously known as Aerospace Medical & Healthcare Technology Co., Ltd. (航天醫療健康科技有限公司) from November 2018 to April 2024 and from October 2020 to July 2023, respectively. In addition, from June 2012 to November 2018, he successively served several positions, including the head of the asset operation department (資產運營部部長), a deputy general manager and the

secretary of the board at AISINO CO. LTD. (航天信息股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600271). From July 1999 to June 2012, Mr. Chen successively served several positions, including a deputy director of the planning department of the development planning division (發展計劃部規劃處副處長) and the director of the fixed assets investment department of the development planning division (發展計劃部固定資產投資處處長) at China Aerospace Science and Industry Corporation (中國航天科工集團公司, currently known as China Aerospace Science and Industry Corporation Limited (中國航天科工集團有限公司)).

Mr. Chen obtained a bachelor's degree (majored in Architecture and Engineering) in July 1995 from Chongqing University (重慶大學), and he studied as a part-time graduate student and obtained a master's degree in management science and engineering in October 2018 from Harbin Institute of Technology (哈爾濱工業大學).

Mr. Chen and the Company entered into a service contract on 16 May 2024, pursuant to which Mr. Chen was appointed as an executive Director with effect from 16 May 2024, and such appointment could be terminated by either Mr. Chen or the Company by giving not less than 90 days' notice in writing. Mr. Chen will hold office as an executive Director until completion of the next annual general meeting of the Company following his appointment and will then be eligible for re-election at that general meeting of the Company. Pursuant to the service contract, the remuneration of Mr. Chen as an executive Director will be considered by the remuneration committee of the Board and subsequently considered and approved by the Board.

As at the date of this announcement, except as disclosed above, Mr. Chen did not (i) have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iii) hold any other directorships in public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iv) hold other positions with the Company or its subsidiaries.

Save as disclosed above, to the best of the knowledge, information and belief of the Directors after having made all reasonable enquiries, there is no information in relation to the appointment of Mr. Chen that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders.

The Board would like to extend its warm welcome to Mr. Chen's role as an executive Director.

CHANGES OF CHAIRPERSON OF THE BOARD, COMPOSITION OF BOARD COMMITTEES, AND AUTHORISED REPRESENTATIVE

Following Ms. Peng's resignation, Mr. Chen, was appointed as the chairman of the Board, the Nomination Committee, and the Strategy Committee, and the Authorised Representative, all with effect from 16 May 2024.

Following Ms. Peng's resignation and upon Mr. Chen's appointment, the composition of the Nomination Committee and the Strategy Committee are as follows:

The Nomination Committee:

- Mr. Chen Shisu (chairman of the committee and executive Director)
- Mr. Xu Ming (non-executive Director)
- Mr. Li Yinquan (independent non-executive Director)
- Mr. Chow Siu Lui (independent non-executive Director)
- Mr. Chan, Hiu Fung Nicholas (independent non-executive Director)

The Strategy Committee:

- Mr. Chen Shisu (chairman of the committee and executive Director)
- Mr. Chan Kai Kong (non-executive Director)
- Mr. Zhu Ziyang (non-executive Director)

By order of the Board
**Genertec Universal Medical Group Company
Limited**
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Beijing, PRC, 16 May 2024

As at the date of this announcement, the executive Directors are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive Directors are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.